Agios Pharmaceuticals (AGIO) Insider Scadden Buys 14,950 Shares

David Scadden Purchases Agios Pharmaceuticals Shares

David Scadden acquired 14,950 shares of Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) on June 28, 2026, adding to his personal holding in the biopharmaceutical firm. This transaction formed part of a coordinated wave of insider buying on June 18, 2026, where several key personnel expanded their equity exposure in the Cambridge-based company.

A Wave of Insider Buying on June 18

The transaction by Scadden did not happen in isolation. On the exact same date of June 18, 2026, Chief Medical Officer Sarah Gheuens picked up 3,000 shares. At the same time, Rahul Ballal, Jay Backstrom, and Jacqualyn Fouse each acquired 14,950 shares, while Cynthia Smith added 2,816 shares to her personal account. This collective buying spree across the leadership team highlights a notable group acquisition of company equity on a single day.

Stock Valuation and Price Action

Shares of Agios Pharmaceuticals change hands around $35.47, resting close to its 50-day moving average of $34.43 and above its 200-day moving average of $30.75. The equity has moved between a 52-week low of $22.24 and a 52-week high of $46.00. With a beta of 0.6, the stock tends to experience less volatility than the wider market, and the company currently commands a market cap of about $2.03 billion.

Recent Earnings and Financial Position

For the period, Agios Pharmaceuticals reported $98.34 million in revenue alongside a revenue growth rate of 2.593%. The firm logged an earnings per share figure of -7.01 and an unwelcome return on equity of -0.34337002, while maintaining a current ratio of 10.221 and a quick ratio of 9.14. Because the bottom line remains negative, the equity carries no meaningful P/E ratio, though its forward P/E sits at -8.579429. Investors can look toward the next earnings report scheduled for October 29, 2026, for updated financial figures.

Analysts Set New Price Targets

Analyst firms continue to adjust their targets for Agios Pharmaceuticals. On October 7, 2026, Truist Securities kept its buy rating with a $37.00 price target, following an earlier update on July 31, 2026, where it held a $39.00 target. B of A Securities kept a buy rating on September 21, 2026, lifting its target to $50.00 from $46.00. JP Morgan maintained a neutral rating with a $34.00 target on August 7, 2026, while Citigroup kept a buy rating at a $52.00 target on July 31, 2026. HC Wainwright & Co. also maintained a buy rating on July 30, 2026, setting a $55.00 price target, and RBC Capital held a sector perform rating with a $32.00 target on July 7, 2026. Across the wider analyst community, the stock maintains a consensus buy recommendation backed by eight analyst opinions and a mean price target of $46.25.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company centered on cellular metabolism therapeutics. The organization develops treatments for conditions such as PK deficiency, sickle cell disease, and thalassemia, deploying specialized enzyme activators and targeted therapies. These insider transactions give observers a window into how the executive team manages personal capital alongside ongoing clinical development.

What to Watch at Agios Pharmaceuticals, Inc.

Market participants will monitor upcoming regulatory updates and clinical trial progress as the company approaches its next earnings announcement on October 29, 2026. Further Form 4 filings will show whether other insiders continue adding to their holdings.